Mastopathy treatment effectiveness in women of reproductive age: A literature review

Authors

  • N.A. Omarbayeva
  • A.B. Askandirova KazIOR
  • N.A. Chichua
  • A.Zh. Abdrakhmanova
  • D.U. Shayakhmetova
  • O.V. Shatkovskaya

DOI:

https://doi.org/10.37800/RM.4.2021.18-22

Keywords:

fibrocystic mastopathy, Vitex аgnus сastus, mammary gland, breast cancer

Abstract

Relevance: Benign breast pathology occurs worldwide in about 80% of women of reproductive age. Various types of mastopathy transform into breast cancer in 3-6% of patients, so they are regarded as risk factors for breast cancer development. Currently, there is no single generally accepted tactic for treating this pathology since the disease course can vary depending on concomitant pathologies or hormonal imbalance in the body. Therefore, mastopathy can be cured not only surgically. One of the main methods of treatment of this pathology is medication, which is based on taking medications aimed primarily at regulating the hormonal background. However, to date, there is no single tactic for treating the disease, and there are no approved, generally accepted recommendations for treating mastopathy.
The study aimed to assess the effectiveness and safety of using the medicinal product BNO 1025 containing an extract of Vitex аgnus сastus in treating the dyshormonal disorders of the mammary glands based on the literature analysis.
Research methods included a review of published results of scientific and clinical studies in the PubMed database for 2010-2021.
Results: The analysis of published research results showed sufficient clinical efficacy and a favorable safety profile of the medicinal product BNO 1025 in fibrocystic mastopathy and a particular advantage of this product over biologically active additives.
Conclusion: Randomized clinical trials (RCT) results demonstrate the high efficacy of VAC treatment in benign dysfunction of the mammary gland. Today, VAC is a drug of choice for the first- and second-line monotherapy for women of childbearing age. We consider it necessary to carefully design an RCT to determine the optimal duration of treatment with the BNO 1025 drug, clarify the effectiveness of different dosages, and verify the results.

References

Кайдарова Д.Р., Абдрахманова А.Ж., Омарбаева Н.А., Байжигитов А.Б., Султансеитов Ш.С., Исмаилов М.Б., Хван Н.С., Аскандирова А.Б. Терапевтическая эффективность торемифена при лечении дисгормональных нарушений молочных желез // Фармация Казахстана. – 2020. – №10. – С. 12-16 [Kajdarova D.R., Abdraxmanova A.Zh., Omarbaeva N.A., Bajzhigitov A.B., Sultanseitov Sh.S., Ismailov M.B., Xvan N.S., Askandirova A.B. Terapevticheskaya e'ffektivnost' toremifena pri lechenii disgormonal'nyx narushenij molochnyx zhelez // Farmaciya Kazaxstana. – 2020. – №10. – S. 12-16]. https://elibrary.ru/item.asp?id=45561134;

Баранов И.И. Роль фитотерапии в консервативном лечении патологии молочных желез // РМЖ. Мать и дитя. – 2013. – №14. – С. 755 [Baranov I.I. Rol' fitoterapii v konservativnom lechenii patologii molochnykh zhelez // RMZh. Mat' i ditya. – 2013. – №14. – S. 755] https://www.rmj.ru/articles/ginekologiya/Roly_fitoterapii_v_konservativnom_lechenii_patologii_molochnyh_ghelez/;

Кац И.П., Павлова Е.А., Ордиянц И.М. Роль генетических факторов и иммунных нарушений в развитии доброкачественных заболеваний молочных желез // В кн.: Материалы II Междисциплинарного форума «Медицина молочной железы». – М.: Медиабюро Статус презенс, 2012. – С. 27–31 [Kac I.P., Pavlova E.A., Ordiyanc I.M. Rol' geneticheskix faktorov i immunnyx narushenij v razvitii dobrokachestvennyx zabolevanij molochnyx zhelez // V kn.: Materialy II Mezhdisciplinarnogo foruma «Medicina molochnoj zhelezy». – M.: Mediabyuro Status prezens, 2012. – S. 27–31];

Смоланко И.И., Антоновская Я.В. Современные возможности терапии последствий гиперэстрогении у женщин репродуктивного возраста // Онкология. – 2010. – Т. 12, №2. – С. 1-3. https://www.oncology.kiev.ua/ru/article/6794/sovremennye-vozmozhnosti-terapii-posledstvij-giperestrogenii-u-zhenshhin-reproduktivnogo-vozrasta-6?pdf

4. Вуттке В., Ярри Г., Зайдлова-Вуттке Д., Уварова Е.В., Девятченко Т.Ф., Гуменюк Е.Г., Погодин О.К., Левенец С.А. Терапевтические возможности экстрактов из Авраамова дерева (Vitex Agnus castuc) в гинекологической практике // Здоровье женщины. – 2014. – №4(90). – С. 118 [Vuttke V., Yarri G., Zaydlova-Vuttke D., Uvarova Ye.V., Devyatchenko T.F., Gumenyuk Ye.G., Pogodin O.K., Levenets S.A. Terapevticheskiye vozmozhnosti ekstraktov iz Avraamova dereva (Vitex Agnus castuc) v ginekologicheskoy praktike // Zdorov'ye zhenshchiny. – 2014. – №4(90). – S. 118]. https://www.elibrary.ru/item.asp?id=22575384;

Rani A., Sharma A. The genus Vitex: A review // Pharmacogn. Rev. – 2013. – Vol. 7 (14). – P. 188–198. https://doi.org/10.4103/0973-7847.120522;

Рожкова Н.И., Меских Е.В. Применение Мастодинона при различных формах мастопатии // Опухоли женской репродуктивной системы. – 2010. – № 3. – С. 1-5 [Rozhkova N.I., Meskikh Ye.V. Primeneniye Mastodinona pri razlichnykh formakh mastopatii // Opukholi zhenskoy reproduktivnoy sistemy. – 2010. – № 3. – S. 1-5.] https://cyberleninka.ru/article/n/primenenie-mastodinona-pri-razlichnyh-formah-mastopatii;

Hogner C., Sturm S., Seger C., Stuppner H. Development and validation of a rapid ultra-high-performance liquid chromatography diode array detector method for Vitex agnus-castus // J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. – 2013. – Vol. 927. – P. 181–190. https://doi.org/10.1016/j.jchromb.2013.02.037;

Niazi A., Rahimi V.B., Hatami H., Shirazinia R., Esmailzadeh-Dizaji E., Askari N., Askari V.R. Effective Medicinal Plants in the Treatment of the Cyclic Mastalgia (Breast Pain) // J. Pharmacopuncture. – 2019. – Vol. 22(3). – P. 131-139. https://doi.org/10.3831/KPI.2019.22.017;

Mirghafourvand M., Mohammad-Alizadeh-Charandabi S., Ahmadpour P., Javadzadeh Y. Effects of Vitex agnus and Flaxseed on cyclic mastalgia: A randomized controlled trial // Complement. Ther. Med. – 2016. – Vol. 24. – P. 90–95. https://doi.org/10.1016/j.ctim.2015.12.009;

Aydin I., Baltaci D., Oncu M. Comparison of Vitex agnus castus with Meloxicam and placebo in treatment of patients with cyclical mastalgia // Duzce Med. J. – 2012. – Vol. 14. – P. 1–5 (in Turkish). https://dergipark.org.tr/en/pub/dtfd/issue/48281/611247;

Торшин И.Ю., Громова О.А., Лиманова О.А. Систематический анализ состава и механизмов молекулярного воздействия стандартизированных экстрактов Vitex Agnus-castus // Трудный пациент. – 2015. – № 13(1-2). – С. 10-27 [Torshin I.YU., Gromova O.A., Limanova O.A. Sistematicheskiy analiz sostava i mekhanizmov molekulyarnogo vozdeystviya standartizirovannykh ekstraktov Vitex Agnus-castus // Trudnyy patsiyent. – 2015. – № 13(1-2). – S. 10-27]. https://t-pacient.ru/wp-content/uploads/2015/03/TP-1-2-2015.pdf;

Мустафин Ч.К. Современная диагностика заболеваний молочных желез. Главный врач. – 2014. – №2(39). – C. 20-23 [Mustafin Ch.K. Sovremennaya diagnostika zabolevanij molochnyx zhelez. Glavnyj vrach. – 2014. – №2(39). – C. 20-23]. https://cyberleninka.ru/article/n/sovremennaya-diagnostika-zabolevaniy-molochnyh-zhelez/viewer;

Rafieian-Kopaei M., Movahedi M. Systematic Review of Premenstrual, Postmenstrual and Infertility Disorders of Vitex Agnus Castus // Electron. Physician. – 2017. – Vol. 9(1). – P. 3685–3689. https://doi.org/10.19082/3685.

Additional Files

Published

2021-12-30

How to Cite

[1]
Omarbayeva Н., Askandirova А., Chichua Н., Abdrakhmanova А., Shayakhmetova Д. and Shatkovskaya О. 2021. Mastopathy treatment effectiveness in women of reproductive age: A literature review. Reproductive Medicine. 4 (49) (Dec. 2021), 16–21. DOI:https://doi.org/10.37800/RM.4.2021.18-22.

Issue

No. 4 (49) (2021): Reproductive medicine

Section

Статьи

License

The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.